Emapalumab clinical trials
Also written Gamifant and NI-0501.
How each study uses Emapalumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Emapalumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 20 Nov 2018 · GAMIFANT · BLA 761107 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
21 studies that test it; most in 2026 (6)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 3 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 11 · Other 10
Swedish Orphan Biovitrum (11) · Children's Healthcare of Atlanta (1) · NYU Langone Health (1) · University of California, San Francisco (1) · City of Hope Medical Center (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · University of Miami (1) · M.D. Anderson Cancer Center (1)
Often tested with
Tested in the same studies.
Cyclophosphamide (1) · Mycophenolic Acid (1) · Tacrolimus (1) · Fludarabine (1) · Dexamethasone (1) · Interleukin 1 Receptor Antagonist Protein (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test Emapalumab.
- Mar 2027A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory ConditionPhase 2 · Joseph Oved
- Jul 2027Emapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) StudyPhase 2 · University of Miami
Studies
Open first, then newest update. How each study uses Emapalumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 21
- Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell TransplantRecruitingPhase 1City of Hope Medical CenterNCT06996119Written as EmapalumabHow we know
- Randomized Stepped Wedge Study of Emapalumab in APECED EnteritisRecruitingPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT07202598Written as EmapalumabHow we know
- Emapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) StudyRecruitingPhase 2University of MiamiNCT07486869Written as EmapalumabHow we know
- A Pilot Study of Emapalumab for the Treatment of CAR T-Cell Therapy-Associated Prolonged CytopeniaRecruitingPhase 2M.D. Anderson Cancer CenterNCT06285825Written as EmapalumabHow we know
- Severe Hepatitis Intervention With Emapalumab for Liver DiseaseNot yet recruitingPhase 2Children's Healthcare of AtlantaNCT07744919Written as EmapalumabHow we know
- A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory ConditionRecruitingPhase 2Joseph OvedNCT05787574Written as EmapalumabHow we know
- Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANSNot yet recruitingPhase 2NYU Langone HealthNCT07567014Written as EmapalumabHow we know
- Targeting Interferon Gamma With Emapalumab to Lung Transplant Recipients With Interferon Gamma-high Acute Lung Allograft DysfunctionNot yet recruitingPhase 2University of California, San FranciscoNCT07538336Written as EmapalumabHow we know
- Prevention of Graft Rejection in Hematopoietic Stem Cell Transplant (HSCT) RecipientsRecruitingEarly Phase 1Children's Hospital Medical Center, CincinnatiNCT07244419Written as Emapalumab 3 mg/kgHow we know
- A Study of Emapalumab for Pediatric Aplastic AnemiaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06430788Written as EmapalumabHow we know
- A Post-authorization Study to Describe the Safety and Efficacy of Emapalumab for the Treatment of pHLH in Treatment Experienced Chinese PatientsCompletedPhase 4Swedish Orphan BiovitrumNCT05744063Written as Emapalumab-Lzsg 5 MG/ML [Gamifant]How we know
- Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLECompletedPhase 3Swedish Orphan BiovitrumNCT05001737Written as EmapalumabHow we know
- Study to Assess the Efficacy and Safety of Emapalumab in Primary Haemophagocytic LymphohistiocytosisCompletedPhase 3Swedish Orphan BiovitrumNCT03312751Written as EmapalumabHow we know
- Study to Investigate the Pharmacokinetics, Pharmacodynamics and Assess the Efficacy and Safety to Support Dose Selection of Emapalumab in Pre-empting Graft Failure in Patients at High Risk After HSCT.TerminatedPhase 2Swedish Orphan BiovitrumNCT04731298Written as EmapalumabHow we know
- A Study to Evaluate Emapalumab in Japanese Healthy Volunteers.CompletedPhase 1Swedish Orphan BiovitrumNCT04765553Written as NI-0501How we know
- A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Emapalumab in Adult Patients With HLHTerminatedPhase 2/3Swedish Orphan BiovitrumNCT03985423Written as Emapalumab-LzsgHow we know
- First in Human Study of an Anti-IFN Gamma Monoclonal Antibody in Healthy VolunteersCompletedPhase 1Swedish Orphan BiovitrumNCT01459562Written as NI-0501How we know
- Study to Investigate Safety, Efficacy of an Anti-IFNγ mAb in Children With Primary Haemophagocytic LymphohistiocytosisCompletedPhase 2/3Swedish Orphan BiovitrumNCT01818492Written as NI-0501How we know
- A Study for Long-term Follow-up of Hemophagocytic Lymphohistiocytosis (HLH) Participants Who Received Treatment With Emapalumab (NI-0501), an Anti-interferon Gamma Monoclonal AntibodyCompletedPhase 2/3Swedish Orphan BiovitrumNCT02069899Written as EmapalumabHow we know
- A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH)CompletedPhase 2Swedish Orphan BiovitrumNCT03311854Written as EmapalumabHow we know
See all 21 studies that test Emapalumab →
Given beside what is tested · 1 — Emapalumab is usual care or a partner of the new treatment
Codes
What other systems call Emapalumab · ClinicalTrials.gg INT001177
- MeSH (NLM) C000644327EmapalumabOne source ClinicalTrials.gov
- UNII (FDA) 3S252O2Z4XEMAPALUMABConfirmed FDA, Wikidata
- RxNorm 2104604One source FDA
- Wikidata Q28209889emapalumabConfirmed FDA, Wikidata
- NCI Thesaurus C127123EmapalumabOne source FDA
- DrugBank DB14724One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000644327 | Emapalumab | One source ClinicalTrials.gov |
| UNII (FDA) | 3S252O2Z4X | EMAPALUMAB | Confirmed FDA, Wikidata |
| RxNorm | 2104604 | — | One source FDA |
| Wikidata | Q28209889 | emapalumab | Confirmed FDA, Wikidata |
| NCI Thesaurus | C127123 | Emapalumab | One source FDA |
| DrugBank | DB14724 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.